Critical appraisal of bevacizumab in the treatment of ovarian cancer

Critical appraisal of bevacizumab in the treatment of ovarian cancer

Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, JapanAbstract: Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized mo...

Full description

Bibliographic Details
Main Authors:	Yoshida H, Yabuno A, Fujiwara K
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-04-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/critical-appraisal-of-bevacizumab-in-the-treatment-of-ovarian-cancer-peer-reviewed-article-DDDT

Similar Items

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

The role of bevacizumab in the treatment of patients with ovarian and cervical cancer
by: S V Khokhlova
Published: (2017-01-01)

Beyond Bevacizumab: an outlook to new antiangiogenics for the treatment of ovarian cancer
by: Sven eMahner, et al.
Published: (2015-10-01)

Bevacizumab in maintenance therapy for ovarian cancer patients
by: L. Yu. Vladimirova, et al.
Published: (2020-08-01)

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
by: Christophe Lallemand, et al.
Published: (2020-10-01)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
by: Yingwen Wang, et al.
Published: (2023-03-01)

Bevacizumab in advanced ovarian cancer: when, what for and why?
by: A S Tjulandina
Published: (2014-09-01)

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
by: Caitlin Lazurko, et al.
Published: (2023-09-01)

Clinical case use bevacizumab for patient with metastatic ovarian cancer
by: M. R. Oganyan, et al.
Published: (2014-07-01)

A review on critical appraisal and pathogenesis of polycystic ovarian syndrome
by: Younis Ahmad Hajam, et al.
Published: (2024-03-01)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer
by: Robert Hettle, et al.
Published: (2021-09-01)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
by: Irena Conic, et al.
Published: (2022-04-01)

Abdominal wall perforation in a patient with recurrent epithelial ovarian cancer after bevacizumab treatment
by: Efnan Algin, et al.
Published: (2016-08-01)

Critical appraisal of trastuzumab in treatment of advanced stomach cancer
by: Judith Meza-Junco, et al.
Published: (2011-03-01)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
by: Jo-Ni Hung, et al.
Published: (2022-05-01)

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer
by: Stuart A. Ostby, et al.
Published: (2020-05-01)

Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer
by: Jun Li, et al.
Published: (2021-01-01)

Testing Doses and Treatment Timelines of Anti-Angiogenic Drug Bevacizumab Numerically as a Single-Agent for the Treatment of Ovarian Cancer
by: Dharma Raj Khatiwada, et al.
Published: (2023-01-01)

Websites for critical appraisal in diagnosis and treatment
by: Aldemar Araújo Castro

Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis
by: Li Song, et al.
Published: (2023-06-01)

The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives
by: Klaudia Żak, et al.
Published: (2024-03-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)

Critical Appraisal
by: Prof. Dr. S. Akhtar Hussain Bokhari
Published: (2020-01-01)

Critical Appraisal
by: manijeh eskandari, et al.
Published: (2011-10-01)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
by: Chih-Lin Mao, et al.
Published: (2022-06-01)

Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
by: Soshi Kusunoki, et al.
Published: (2018-10-01)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
by: Mattias Neyt, et al.
Published: (2018-01-01)

Critical appraisal of paroxetine for the treatment of vasomotor symptoms
by: Carroll DG, et al.
Published: (2015-06-01)

Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients
by: Nan Zhang, et al.
Published: (2023-04-01)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
by: Francesca Ricci, et al.
Published: (2017-05-01)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
by: Dominique Berton, et al.
Published: (2021-09-01)

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
by: Jubb, A, et al.
Published: (2011)

1-CRITICAL APPRAISAL
by: Thamer A Hamdan
Published: (2008-06-01)

New treatment options for fibromyalgia: critical appraisal of duloxetine
by: Nurcan &Uuml;&ccedil;eyler, et al.
Published: (2008-06-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-01-01)

Bevacizumab for the Treatment of Glioblastoma
by: Miguel J. Gil-Gil, et al.
Published: (2013-06-01)

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series
by: Shannon M. Glynn, et al.
Published: (2024-06-01)

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
by: Sadaba B, et al.
Published: (2013-05-01)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
by: Warnke C, et al.
Published: (2011-09-01)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639)
by: Hidekatsu Nakai, et al.
Published: (2023-04-01)